Intranasal Fentanyl for Episodic Breathlessness

Journal of Pain and Symptom Management

Volumn 36, Issue 6, 2008, Pages

  Sitte, Thomas ^a   Bausewein, Claudia ^b  

^a Palliativversorgung Hessen   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DYSPNEA; FEMALE; HUMAN; LETTER; MALE; OXYGEN THERAPY; PALLIATIVE THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DYSPNEA; FEMALE; FENTANYL; HUMANS; MALE; TREATMENT OUTCOME;

EID: 56949083592     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.08.002     Document Type: Letter

References (13)

1. Jennings A.L., Davies A.N., Higgins J.P., and Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews 4 (2001) CD002066
2. Abernethy A.P., Currow D., Frith P., et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327 (2003) 523-528
3. Dale O., Hjortkjaer R., and Kharasch E.D. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46 7 (2002) 759-770
4. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 20 4 (2000) 253-258
5. Sarkar M.A. Drug metabolism in the nasal mucosa. Pharm Res 9 1 (1992) 1-9
6. Takala A., Kaasalainen V., Seppala T., Kalso E., and Olkkola K.T. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 41 2 (1997) 309-312
7. Eriksen J., Jensen N.H., Kamp-Jensen M., et al. The systemic availability of buprenorphine administered by nasal spray. J Pharm Pharmacol 41 11 (1989) 803-805
8. Striebel H.W., Kramer J., Luhmann I., Rohierse-Hohler I., and Rieger A. Pharmacokinetics of intranasal fentanyl. [in German]. Schmerz 7 2 (1993) 122-125
9. Lim S., Paech M.J., Sunderland B., et al. Pharmacokinetics of nasal fentanyl. J Pharm Pract Res 33 1 (2003) 59-63
10. Striebel H.W., Koenigs D., and Kramer J. Postoperative pain management by intranasal demand-adapted fentanyl titration. Anesthesiology 77 2 (1992) 281-285
11. Coyne P.J., Viswanathan R., and Smith T.J. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 23 2 (2002) 157-160
12. Benitez-Rosario M.A., Martin A.S., and Feria M. Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. J Pain Symptom Manage 30 5 (2005) 395-397
13. Christrup L.L., Foster D., Popper L.D., Troen T., and Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 30 3 (2008) 469-481